Abstracts Archive - Page 464 of 2605 - ACR Meeting Abstracts

Abstract Number: 2414 • ACR Convergence 2023
Relapse in Giant Cell Arteritis Treated with Tocilizumab. Predictive Factors
Fernando López¹, Javier Loricera², Ivan Ferraz Amaro³, Santos Castañeda⁴, Clara Moriano Morales⁵, Javier Narvaez⁶, Vicente Aldasoro⁷, Olga Maiz⁸, Rafael Benito Melero-Gonzalez⁹, Juan I. Villa¹⁰, PALOMA VELA¹¹, Susana Romero Yuste¹², Jose L. Callejas¹³, Eugenio De Miguel¹⁴, Eva Galindez-Agirregoikoa¹⁵, Francisca Sivera¹⁶, Jesús Carlos Fernández López¹⁷, Arturo Llobell¹⁸, Julio Sánchez-Martín¹⁹, Calderon Goercke², Lara Sanchez-Bilbao²⁰, Jose L. Hernández²¹ and Ricardo Blanco²², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de León, León, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Hospital Universitario de Navarra, Pamplona, Spain, ⁸Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, ⁹CHU Vigo, O Carballino, Spain, ¹⁰Department of Rheumatology, Hospital Sierrallana, Torrelavega, Torrelavega, Spain, ¹¹Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ¹²Complexo Hospitalario Universitario, Pontevedra, Spain, ¹³Unit of Systemic Autoimmune Diseases, Hospital San Cecilio, Granada, Spain, ¹⁴Hospital Universitario La Paz, Madrid, Spain, ¹⁵Basurto University Hospital, Bilbao, Spain, ¹⁶Elda General University Hospital, Elda, Spain, ¹⁷Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁸Parc Tauli University Hospital, Barcelona, Spain, ¹⁹Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, ²⁰Hospital Universitario Marques de Valdecilla, Santander, Spain, ²¹Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) is the only biologic therapy approved for giant cell arteritis (GCA). Clinical trial with TCZ in GCA was performed with intravenous (iv)…
Abstract Number: 2415 • ACR Convergence 2023
Giant Cell Arteritis Is Associated with Worse Hospital Outcomes in Aortic Aneurysm/Dissection Hospitalizations: A Nationwide United States Population-Based Study
Artem Minalyan¹, Christopher Hino¹, Emily He¹, Osahon Idolor², Chinenye Osuorji³, Nneka Chukwu⁴, Ehizogie Edigin¹ and Vaneet Sandhu⁵, ¹Loma Linda University Health, Loma Linda, CA, ²Piedmont Athens Regional Hospital, Atlanta, GA, ³Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁴Nuvance Health Internal Medicine Residency, Poughkeepsie, NY, ⁵Loma Linda University, Loma Linda, CA
Background/Purpose: Giant Cell Arteritis (GCA) is a known risk factor for Aortic Aneurysm/Dissection (AAD). However, it is unclear if patients with GCA have worse hospital…
Abstract Number: 2400 • ACR Convergence 2023
Applanation Tonometry of the Temporal Arteries in Participants with Suspected Giant Cell Arteritis: A Proof of Concept
Jean-Paul Makhzoum¹, Stephanie Ducharme-Benard², Samer Hussein², Rosalie-Selene Meunier², Carolyn Ross³, Alik Chamlian⁴, Jonathan Ducharme⁵, Leia Chamlian⁴, Alae Dhahbi⁴, Christian Pagnoux⁶ and Remi Goupil⁷, ¹Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Canadian Network for Research on Vasculitides, Montreal, QC, Canada, ²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ³Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁴Laval University, Montreal, QC, Canada, ⁵University of Sherbrooke, Montreal, QC, Canada, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷Hopital du Sacre-Coeur de Montreal, University of Montreal, Montreal, QC, Canada
Background/Purpose: Applanation tonometry (ATn) is a non-invasive, point-of-care tool used to capture arterial pressure waveforms. It can measure arterial pulse wave velocity (PWV), a marker…
Abstract Number: 2412 • ACR Convergence 2023
Evaluation of the Pretest Probability Score, Ultrasound and Biopsy on GCA Diagnose: Data from Real Clinical Practice
María del Carmen San José Méndez¹, Uxía Couto Lareo¹, Vanesa Balboa Barreiro², Francisco J. Blanco¹, Bruno de aspe de la iglesia¹, Antonio Atanes Sandoval³, Diego Dios Santos¹, Jesús Carlos Fernández López¹, Mercedes Freire González¹, Guillermo González Arribas¹, Genaro Graña Gil¹, Natividad Oreiro Villar¹, Jose Antonio Pinto Tasende¹, Francisco Javier De Toro Santos¹, Clara Ventin Rodriguez¹, Maite silva díaz³ and Ana Lois Iglesias¹, ¹Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ²Clinic epidemiology and biostatistics department. Complejo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ³Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain
Background/Purpose: Giant cell arteritis (GCA) affects large and medium size arteries. Biopsy was considered the gold standard in the diagnosis1, but in the last years…
Abstract Number: 2418 • ACR Convergence 2023
Effectiveness of Dose Spacing with Tocilizumab in Giant Cell Arteritis Treatment
Sharon Cowley¹, Colm Kirby², Patricia Harkins³, Richard Conway⁴, Grainne Murphy⁵ and David Kane⁶, ¹Tallaght University Hospital, Dublin, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Ireland, ³St James's Hospital, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Cork University Hospital, Cork, Ireland, ⁶Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: The only steroid sparing agent approved for treatment of Giant Cell Arteritis (GCA) is the anti-interleukin-6 receptor antagonist tocilizumab. There remains uncertainty regarding treatment…
Abstract Number: 2419 • ACR Convergence 2023
Visual Manifestations in Giant Cell Arteritis: Identification of Risk Factors from the ARTESER Registry
Juan Molina-Collada¹, Marta Domínguez², Rafael Benito Melero-Gonzalez³, Elisa Fernandez-Fernandez⁴, Maria. T Silva-Diaz⁵, Joaquín M. Belzunegui⁶, Ismael González⁷, Julio Sanchez Martin⁸, Javier Narvaez⁹, Eva Galíndez¹⁰, javier Mendizábal¹¹, Leticia Leon Mateos¹², Javier Loricera⁸, Alejandro Muñoz¹³, Santos Castañeda¹⁴, Iván Castellvi¹⁵, Marina Tortosa-Cabañas¹⁶, Vanesa Navarro¹⁷, Carlos Galisteo¹⁸, Ivette Casafont-Solé¹⁹, Jose Andres Roman Ivorra²⁰, TAREK CARLOS SALMAN MONTE²¹, Margarida Rocha²², Carlota Laura Iñiguez²³, Maria Vanesa Hernandez Hernandez²⁴, Cristina Campos²⁵, María Alcalde²⁶, Antonio Juan Mas²⁷, Francisco Javier Prado²⁸ and Ricardo Blanco²⁹, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³CHU Vigo, O Carballino, Spain, ⁴La Paz University Hospital, Madrid, Spain, ⁵Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Hospital Universitario Donostia, Donostia, Spain, ⁷Hospital Universitario de León, León, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Hospital Universitario de Basurto, Bilbao, Spain, ¹¹Complejo Hospitalario de Navarra, Pamplona, Spain, ¹²IDISSC Hospital Clinico San Carlos, Madrid, Spain, ¹³Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Spain, ¹⁵Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ¹⁶Ramon y Cajal University Hospital, Madrid, Spain, ¹⁷H Moisès Broggi, Sant Joan Despí, Barcelona, Spain, ¹⁸Hospital Universitario Parc Taulí, Barcelona, Spain, ¹⁹Hospital Germans Trias i Pujol, Badalona, Spain, ²⁰Hospital Universitari i Politècnic la Fe, Valencia, Spain, ²¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²²Osakidetza, Bilbo, Spain, ²³Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁴Hospital Universitario de Canarias, La Laguna, Spain, ²⁵Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ²⁶Hospital Severo Ochoa, Madrid, Spain, ²⁷Hospital Universitario Son Llàtzer, Mallorca, Spain, ²⁸Research department Hospital Infantil de México Federico Gómez, Mexico City, Mexico, ²⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Visual loss is one of the most feared complications in giant cell arteritis (GCA). Some factors have been previously associated with visual loss, as…
Abstract Number: 2417 • ACR Convergence 2023
Influence of Histological Tempol Artery Biopsy Findings on Outcomes of Biopsy-proven Giant Cell Arteritis in Italian Patients : A Long Single Center Follow-up Study
LUIGI BOIARDI¹, PIERLUIGI MACCHIONI², Francesco Muratore³, Elena Galli⁴, chiara marvisi⁴, caterina Ricordi⁴, federica Macaluso¹, alberto cavazza⁴, Stefania Croci⁴ and Carlo Salvarani⁵, ¹IRCCS REGGIO EMILIA, Reggio Emilia, Italy, ²Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, ³IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, ⁵Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Few studies have evaluted the influence of histological features of temporal artery biopsy (TAB) on disease outcome in giant cell arteritis (GCA) patients. Our…
Abstract Number: 2413 • ACR Convergence 2023
Janus Kinase Inhibitors in Giant Cell Arteritis in Clinical Practice. Real-World Clinical Practice Study and Literature Review
Fernando López¹, Javier Loricera², Toluwalase Tofade³, Diana Prieto-Peña², Susana Romero Yuste⁴, Eugenio De Miguel⁵, Anne Riveros-Frutos⁶, Ivan Ferraz Amaro⁷, Santos Castañeda⁸, Eztizen Labrador-Sánchez⁹, Olga Maiz¹⁰, Elena Becerra-Fernández¹¹, Javier Narvaez¹², Eva Galindez-Agirregoikoa¹³, Ismael González¹⁴, Ana Urruticoechea¹⁵, Sebastian Unizony¹⁶ and Ricardo Blanco¹⁷, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Neurology Department, Massachusetts General Hospital, Boston, MA, ⁴Complexo Hospitalario Universitario, Pontevedra, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Hospital Universitario San Pedro, Laguardia, Spain, ¹⁰Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, ¹¹Department of Rheumatology, Hospital Universitario de Torrevieja, London, United Kingdom, ¹²Hospital Universitario de Bellvitge, Barcelona, Spain, ¹³Basurto University Hospital, Bilbao, Spain, ¹⁴Hospital Universitario de León, León, Spain, ¹⁵Hospital Can Misses, Ibiza, Spain, ¹⁶Massachusetts General Hospital, Winchester, MA, ¹⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Patients with giant cell arteritis (GCA) can relapse despite glucocorticoids, methotrexate and tocilizumab treatment. The JAK/STAT signalling pathway is involved in the pathogenesis of…
Abstract Number: 2404 • ACR Convergence 2023
Subclinical Giant Cell Arteritis in Polimialgia Rheumatica: A Biomarker of High Relapse Risk
Eugenio De Miguel¹, Rositsa Karalilova², PIERLUIGI MACCHIONI³, Cristina Ponte⁴, Edoardo Conticini⁵, Alessandro Tomelleri⁶, Sara Monti⁷, Irene Monjo¹, Zguro Batalov², Giulia Klinowski⁸, Paolo Falsetti⁹, David Kane¹⁰, Corrado Campochiaro¹¹ and Alojzija Hocevar¹², ¹Hospital Universitario La Paz, Madrid, Spain, ²Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ³Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁵Tallaght University Hospital, Dublin, Ireland, ⁶Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ⁷Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁸IRCCS-S.Maria Nuova, Reggio Emilia, Italy, ⁹San Raffaele Scientific Institute, Siena, Italy, ¹⁰Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, ¹¹IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ¹²Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Around 20% of polymyalgia rheumatica (PMR) patients without clinical symptoms of giant cell arteritis (GCA) have subclinical GCA by image or byopsy1. However, there…
Abstract Number: 2344 • ACR Convergence 2023
Telitacicept versus Belimumab for Patients with Active Systemic Lupus Erythematosus: A Retrospective, Multicenter, Real-world Observational Study
Zhu Chen¹, Huizhi Jin¹, Yujing Li¹, Guosheng Wang¹, Xiaomei Li², Zhijun Li³, Lin Niu⁴ and Haifeng Pan⁵, ¹University of Science and Technology of China, Hefei, China, ²University of Science and Technology of China, Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Hefei, China, ³Bengbu Medical University, Bengbu, China, ⁴Fuyang People's Hospital, Fuyang, China, ⁵Anhui Medical University, Hefei, China
Background/Purpose: The past decade has witnessed the innovation of several biologics in the treatment of systemic lupus erythematosus (SLE), most of which target B cells,…
Abstract Number: 2424 • ACR Convergence 2023
Exploring the Limit of Image Resolution for Human Expert Classification of Vascular Ultrasound Images in Giant Cell Arteritis and Healthy Subjects: The GCA-US-AI Project
Valentin Sebastian Schäfer¹, Stavros Chrysidis², Christian Dejaco³, Sara Monti⁴, Matthew Koster⁵, Pantelis Karakostas¹, Wolfgang Schmidt⁶, Eugenio De Miguel⁷, Christina Duftner⁸, Alojzija Hocevar⁹, Annamaria Iagnocco¹⁰, Marcin Milchert¹¹, Chetan Mukhtyar¹², Cristina Ponte¹³, Lene Terslev¹⁴, Tanaz Kermani¹⁵, Uffe Møller Døhn¹⁶, Berit Dalsgaard Nielsen¹⁷, Aaron Juche¹⁸, Luca Seitz¹⁹, Minna Kohler²⁰, Kresten Keller²¹, Rositsa Karalilova²², Thomas Daikeler²³, Sarah Mackie²⁴, Karina Torralba²⁵, Kornelis van der Geest²⁶, Dennis Boumans²⁷, Philipp Bosch²⁸, Alessandro Tomelleri²⁹, Markus Aschwanden³⁰, Peter Brossart¹, Charlotte Behning³¹ and Claus Juergen Bauer¹, ¹Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, ²Department of Rheumatology, Southwest Jutland Hospital Esbjerg, Esbjerg, Denmark, ³Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, ⁴Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁵Mayo Clinic, Rochester, MN, ⁶Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, ⁷Hospital Universitario La Paz, Madrid, Spain, ⁸Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, ⁹Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁰University of Turin, Roma, Italy, ¹¹Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ¹²Vasculitis service, Rheumatology department, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ¹³Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ¹⁴Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ¹⁵Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ¹⁶Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ¹⁷Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Medicine, The Regional Hospital in Horsens, Horsens, Denmark, ¹⁸Department of Rheumatology, Immanuel Hospital, Berlin, Germany, ¹⁹Rheumatology and Immunology, Inselspital University Hospital Bern, Bern, Switzerland, ²⁰Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²¹Department of Rheumatology, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ²²Clinic of Rheumatology, Medical University Plovdiv, Plovdiv, Bulgaria, ²³Clinic for Rheumatology, University Hospital Basel, Basel, Switzerland, ²⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²⁵Division of Rheumatology, Department of Medicine, Loma Linda University School of Medicine, Loma Linda, CA, ²⁶Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²⁷Rheumatology and Clinical Immunology, Hospital Group Twente, Almelo, Netherlands, ²⁸Medical University of Graz, Graz, Austria, ²⁹Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ³⁰Department of Angiology, University Hospital Basel, Basel, Switzerland, ³¹Institute of Medical Biometry, Informatics and Epidemiology, University Hospital of Bonn, Bonn, Germany
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in adults, necessitating prompt diagnosis to prevent severe complications. However, access to expert…
Abstract Number: 2397 • ACR Convergence 2023
Impact of Exposure to Environmental Air Pollution on the Onset of Giant Cell Arteritis
Milena Bond¹, Alessandro Tomelleri², Maria Antonietta Reatini³, Corrado Campochiaro⁴, Giorgio Cattani³, Lorenzo Dagna⁵, Maurizio Rossini⁶, Christian Dejaco⁷ and Giovanni Adami⁶, ¹Azienda sanitaria dell'Alto Adige, Merano, Italy, ²Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ³Italian Institute for Environmental Protection and Research, Rome, Italy, ⁴IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ⁵Department of Internal Medicine, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, ⁶Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy, ⁷Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy
Background/Purpose: Environmental air pollution (AP) has been found to affect vascular inflammation and to contribute to the risk of onset and flare of autoimmune diseases1,2.…
Abstract Number: 2351 • ACR Convergence 2023
Health Outcomes Among Patients (Pts) with SLE Initiating Belimumab (BEL) with and Without the Use of Immunosuppressants in the Previous 2 Years
Yan Chen¹, Karen Worley², Brendan Rabideau¹, Bernard Rubin³, Benson Wu¹, Rose Chang¹ and Maral DerSarkissian¹, ¹Analysis Group, Boston, MA, ²GlaxoSmithKline, US Value Evidence and Outcomes, Cincinnati, OH, ³GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC
Background/Purpose: BEL efficacy in pts with SLE has been previously demonstrated in clinical and real-world studies.1 However, there are limited data on differences in outcomes…
Abstract Number: 2356 • ACR Convergence 2023
A Macrophage-Specific Mechanism for Mycophenolate Mofetil in the Treatment of Systemic Sclerosis
Emily Morris, Rezvan Parvizi, Patricia Pioli and Michael Whitfield, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by inflammation and fibrosis. Treatment with mycophenolate mofetil (MMF), an inhibitor of lymphocyte…
Abstract Number: 2363 • ACR Convergence 2023
Increase in Macrophage Infiltration in Scleroderma Esophageal Mucosa Is Associated with Motility and Mucosal Complications
Tai-Ju Lee¹, Ting-Yuan Lan¹, Ko-Jen Li², Song-Chou Hsieh² and Ping-Huei Tseng³, ¹National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ²National Taiwan University Hospital, Taipei, Taiwan, ³National Taiwan University Hospital, Taipei City, Taiwan
Background/Purpose: The macrophage activation is elevated in systemic sclerosis (SSc) patients, and is implicated in pathogenesis of tissue inflammation, fibrosis, and the development of skin…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].